Loading...
XNYS
BHC
Market cap2.73bUSD
Dec 04, Last price  
7.38USD
1D
4.68%
1Q
0.41%
Jan 2017
-49.17%
Name

Bausch Health Companies Inc

Chart & Performance

D1W1MN
XNYS:BHC chart
P/E
P/S
0.28
EPS
Div Yield, %
Shrs. gr., 5y
0.89%
Rev. gr., 5y
2.28%
Revenues
9.63b
+9.91%
935,536,0001,070,475,000842,818,000757,178,000820,430,0001,181,237,0002,463,450,0003,546,626,0005,769,605,0008,263,500,00010,498,800,0009,674,000,0008,724,000,0008,380,000,0008,601,000,0008,027,000,0008,434,000,0008,124,000,0008,757,000,0009,625,000,000
Net income
-46m
L-92.23%
89,027,000203,938,000195,539,000199,904,000176,455,000-208,193,000159,559,000-116,025,000-866,142,000913,500,000-266,200,000-2,409,000,0002,404,000,000-4,148,000,000-1,783,000,000-559,000,000-937,000,000-212,000,000-592,000,000-46,000,000
CFO
1.60b
+54.75%
498,109,000521,934,000340,853,000204,325,000360,897,000263,191,000676,473,000656,578,0001,041,957,0002,294,700,0002,200,400,0002,087,000,0002,290,000,0001,501,000,0001,501,000,0001,111,000,0001,426,000,000-728,000,0001,032,000,0001,597,000,000
Dividend
Nov 10, 20101 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
IPO date
Sep 20, 1994
Employees
19,900
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT